Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R35-HL135824)
Received: 10 September 2020
Accepted: 14 February 2021
First Online: 1 March 2021
Ethics approval and consent to participate
: The University of Michigan Internal Review Board (IRBMED) approved all study protocols and procedures. All participants provided written informed consent for biospecimen collection, electronic health data, future and ongoing use of data for undefined research, and re-contact in future studies (HUM00052866). The University of Michigan IRBMED approved the protocol and procedures for returning research level genetic results (HUM00052866). Separate written informed consent was provided by the participants with pathogenic variants who received CLIA laboratory genetic testing and participated in the survey study (HUM00146932). This study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: Dr. Willer’s spouse works for Regeneron. All other authors have reported that they have no financial or conflicts of interest to disclose.